Simon brings four decades of experience in the global medical technology sector, including senior leadership roles at Smith+Nephew, where he served as Vice President, Healthcare Systems and Vice President, Commercial Access. Across his career, he has helped shape commercial strategy, market access, healthcare system engagement, and adoption pathways for innovative medical technologies.
In this role, Simon will work closely with Embed Biotech’s Board and executive team to support the Company’s commercialisation strategy, with a focus on market access, reimbursement, pricing, healthcare system engagement, and patient access. His appointment strengthens Embed Biotech’s ability to prepare for the global introduction of its bioelectronic platform technology.
“We are pleased to welcome Simon as a Special Advisor,” said Stewart McKinlay, Chair of Embed Biotech. “Simon’s appointment adds significant commercial and market access expertise to Embed Biotech at an important stage in our development. His experience in bringing innovative medical technologies into complex healthcare systems will help us shape a clear path towards adoption, reimbursement, and patient access.”
Simon Dawkins commented: “Embed Biotech is developing a highly innovative approach to bioelectronic medicine with the potential to address significant unmet needs in orthopaedics and, over time, other specialties. I am excited to work with the team, its surgeon advisors, and healthcare system partners to help shape the commercial and market access strategies needed to bring this technology to patients.”
Simon’s appointment reflects Embed Biotech’s continued focus on building the strategic, clinical, and commercial capabilities required to support the successful development and future commercialisation of its technology.
